Reuters: Sanofi-Genzme deal hinges on small price difference

Sanofi-Aventis is seeking to shave an undisclosed amount off its latest Genzyme offer after spending two weeks studying the company's operations, Reuters reports. But is either company prepared to let the deal go for $1 to $2 per share? Report